Abstract
Calretinin, thrombomodulin (CD141), mesothelin, podoplanin, WT-1, GLUT1, BAP-1, h-caldesmon, CD146, and cytokeratin profile [1–3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Husain AN, Colby TV, Ordóñez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma. A consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. 2009;133:1317–31.
Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med. 2008;132:397–401.
King JE, Thatcher N, Pickering CAC, Hasleton PS. Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology. 2006;48:223–32.
Cates JM, Coffing BN, Harris BT, et al. Calretinin expression in tumors of adipose tissue. Hum Pathol. 2006;37(3):312–21.
Ordonez NG. Value of calretinin immunostaining in diagnostic pathology: a review update. Appl Immunohistochem Mol Morphol. 2014;22(6):401–15.
Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18:105–10.
Browning L, Bailey D, Parker A. D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma. J Clin Pathol. 2008;61:293–6.
Hayashi M, Sakata M, Takeda T, et al. Induction of glucose transporter 1 expression through hypoxia-inducible factor 1α under hypoxic conditions in trophoblast-derived cells. J Endocrinol. 2004;183:145–54.
Lee AF, Grown AM, Churg A. IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferation. Am J Surg Pathol. 2013;37(3):421–6.
Mhawech-Fauceglia P, Hermann FR, Rai H, et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am J Clin Pathol. 2010;133:899–908.
Andrici J, Sheen A, Sioson L, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol. 2015;28(10):1360–8.
Cigognetti M, Lonardi S, Fisogni S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043–57.
Hwang H, Sheffield BS, Rodriguez S, et al. Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens. Am J Surg Pathol. 2016;40(1):120–6.
Churg A, Sheffield BS, Galateau-Salle F. New markers for separating benign from malignant mesothelial proliferations. Are we there yet? Arch Pathol Lab Med. 2016;140:318–21.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Tuffaha, M.S.A., Guski, H., Kristiansen, G. (2018). Markers and Immunoprofile of Mesothelioma Tumors of the Peritoneum. In: Immunohistochemistry in Tumor Diagnostics. Springer, Cham. https://doi.org/10.1007/978-3-319-53577-7_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-53577-7_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-53576-0
Online ISBN: 978-3-319-53577-7
eBook Packages: MedicineMedicine (R0)